[ad_1]
Convention Name Contributors
Joern Iffert – UBS Funding Financial institution, Analysis Division
Jon Cox – Kepler Cheuvreux, Analysis Division
Presentation
Operator
Good morning, women and gents, and welcome to this ARYZTA replace name. The decision can have opening remarks by ARYZTA administration and adopted by Q&A. This name is being recorded. Now, I might like handy over to Paul Meade, Head of Investor Relations, to open the decision. Please go forward.
Paul Meade
Head of Communications
Thanks, Laura. Good morning, all, and welcome to right now’s replace. I am joined right now by our Chairman and Interim CEO, Urs Jordi; and our CFO, Martin Huber. I might identical to to remind everybody that the traditional forward-looking assertion of dangers and uncertainties applies to all of right now’s discussions. I might now hand over to Urs.
Urs Jordi
Thanks, Paul. Good morning to everyone for becoming a member of this name. You probably did obtain our advert hoc assertion right now morning. I believe the message is known, and I believe we go immediately into Q&A, Paul.
Paul Meade
Head of Communications
That is positive. Laura, are you able to ask of us if they’ve any questions on the advert hoc on the bulletins, please?
Query-and-Reply Session
Operator
[Operator Instructions] The primary query comes from Jorn Iffert of UBS.
Joern Iffert
UBS Funding Financial institution, Analysis Division
Simply to double examine, are you able to hear me?
Joern Iffert
UBS Funding Financial institution, Analysis Division
Simply a few questions from my facet. The primary one could be, please, I might take them one after the other, if it is okay. There is a fairly important deviation within the second half EBITDA year-over-year versus your steering of round, what’s it, 10% plus/minus not less than. The place precisely is that this deviation coming from? This may be my
[ad_2]
